Lack of FDA Guidance on KRAS Testing Creates Confusion; Pharmas See Lower Sales
February 04, 2009
Lack of FDA Guidance on KRAS Testing Creates Confusion; Pharmas See Lower Sales
Without specific guidance from the FDA regarding KRAS testing, drugmakers Bristol-Myers Squibb and Amgen are facing lower sales of their colorectal cancer drugs Erbitux and Vectibix, and may need to get creative in how they market their drugs to patients and doctors.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Mass General Hospital to Genetically Test All Cancer Patients within One Year
March 11, 2009 / Pharmacogenomics Reporter - DxS Submitting PMA Application for Class III TheraScreen KRAS Assay
March 4, 2009 / Pharmacogenomics Reporter - FDA Update to Erbitux, Vectibix Labels Encourages Rx/Dx Co-development, Industry Expert Says
July 22, 2009 / Pharmacogenomics Reporter - UK Startup DNA Electronics Developing Handheld Device to Detect Genetic Risk for Drug AEs
February 25, 2009 / Pharmacogenomics Reporter - Genomic Health Updates Analysts on Companion Dx Pipeline, New Education Campaign
November 10, 2010 / Pharmacogenomics Reporter